Coronavirus Disease 2019 (COVID-19) was first isolated in Wuhan, China in December 2019. It
is rapidly spreading worldwide, posing a severe threat to global health. Many therapeutics
have been investigated for the treatment of this disease with inconclusive outcomes.
Anakinra - an interleukin (IL)-1 receptor antagonist - had showed survival benefits in
patients with macrophage activation syndrome (MAS) and sepsis and was investigated for the
use in COVID-19 infection with promising outcomes.